全文获取类型
收费全文 | 40794篇 |
免费 | 3615篇 |
国内免费 | 1592篇 |
专业分类
耳鼻咽喉 | 287篇 |
儿科学 | 570篇 |
妇产科学 | 968篇 |
基础医学 | 10170篇 |
口腔科学 | 669篇 |
临床医学 | 2867篇 |
内科学 | 6422篇 |
皮肤病学 | 701篇 |
神经病学 | 1476篇 |
特种医学 | 1551篇 |
外国民族医学 | 3篇 |
外科学 | 1854篇 |
综合类 | 4712篇 |
现状与发展 | 7篇 |
预防医学 | 3040篇 |
眼科学 | 402篇 |
药学 | 3573篇 |
5篇 | |
中国医学 | 943篇 |
肿瘤学 | 5781篇 |
出版年
2024年 | 101篇 |
2023年 | 851篇 |
2022年 | 1604篇 |
2021年 | 1962篇 |
2020年 | 1706篇 |
2019年 | 1532篇 |
2018年 | 1379篇 |
2017年 | 1451篇 |
2016年 | 1518篇 |
2015年 | 1693篇 |
2014年 | 2224篇 |
2013年 | 2648篇 |
2012年 | 1772篇 |
2011年 | 2091篇 |
2010年 | 1641篇 |
2009年 | 1749篇 |
2008年 | 1712篇 |
2007年 | 1759篇 |
2006年 | 1720篇 |
2005年 | 1635篇 |
2004年 | 1487篇 |
2003年 | 1306篇 |
2002年 | 1176篇 |
2001年 | 1076篇 |
2000年 | 943篇 |
1999年 | 780篇 |
1998年 | 753篇 |
1997年 | 676篇 |
1996年 | 622篇 |
1995年 | 586篇 |
1994年 | 628篇 |
1993年 | 427篇 |
1992年 | 442篇 |
1991年 | 333篇 |
1990年 | 310篇 |
1989年 | 255篇 |
1988年 | 224篇 |
1987年 | 146篇 |
1986年 | 156篇 |
1985年 | 199篇 |
1984年 | 164篇 |
1983年 | 66篇 |
1982年 | 86篇 |
1981年 | 94篇 |
1980年 | 91篇 |
1979年 | 66篇 |
1978年 | 56篇 |
1977年 | 35篇 |
1976年 | 36篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
31.
C. Banella M. Ginevrino G. Catalano E. Fabiani G. Falconi M. Divona P. Curzi P. Panetta M.T. Voso N.I. Noguera 《Hematology/oncology and stem cell therapy》2021,14(2):163-168
FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended. 相似文献
32.
33.
34.
SEPT9是13个Septin同源基因家族之一,参与调控众多过程,包括细胞分裂、细胞极化、细胞迁移以及线粒体分裂等。研究表明在众多肿瘤中,SEPT9都发挥着作用,尤其在结直肠肿瘤研究领域,外周血SEPT9基因甲基化检测更是研究热点,其检测的敏感度和特异度相对于其他糖蛋白肿瘤标志物、粪便隐血试验和粪便免疫化学测试等更具有优势,相对于结直肠镜等侵入性检查更节约成本,同时有着更好的依从性。本文对SEPT9的功能、与结直肠癌之间的关系以及对结直肠肿瘤的筛查及诊断价值做一综述。 相似文献
35.
《Vaccine》2016,34(30):3500-3507
We describe the preclinical development of a dengue virus vaccine targeting the dengue virus serotype 2 (DENV2) envelope domain III (EDIII). This study provides proof-of-principle that a dengue EDIII protein scaffold/DNA vaccine can protect against dengue challenge. The dengue vaccine (EDIII-E2) is composed of both a protein particle and a DNA expression plasmid delivered simultaneously via intramuscular injection (protein) and gene gun (DNA) into rhesus macaques. The protein component can contain a maximum of 60 copies of EDIII presented on a multimeric scaffold of Geobacillus stearothermophilus E2 proteins. The DNA component is composed of the EDIII portion of the envelope gene cloned into an expression plasmid. The EDIII-E2 vaccine elicited robust antibody responses to DENV2, with neutralizing antibody responses detectable following the first boost and reaching titers of greater than 1:100,000 following the second and final boost. Vaccinated and naïve groups of macaques were challenged with DENV2. All vaccinated macaques were protected from detectable viremia by infectious assay, while naïve animals had detectable viremia for 2–7 days post-challenge. All naïve macaques had detectable viral RNA from day 2–10 post-challenge. In the EDIII-E2 group, three macaques were negative for viral RNA and three were found to have detectable viral RNA post challenge. Viremia onset was delayed and the duration was shortened relative to naïve controls. The presence of viral RNA post-challenge corresponded to a 10–30-fold boost in neutralization titers 28 days post challenge, whereas no boost was observed in the fully protected animals. Based on these results, we determine that pre-challenge 50% neutralization titers of >1:6000 correlated with sterilizing protection against DENV2 challenge in EDIII-E2 vaccinated macaques. Identification of the critical correlate of protection for the EDIII-E2 platform in the robust non-human primate model lays the groundwork for further development of a tetravalent EDIII-E2 dengue vaccine. 相似文献
36.
37.
38.
Xiaoqing Guo Ji-Eun Seo Xilin Li Nan Mei 《Journal of toxicology and environmental health. Part B, Critical reviews》2020,23(1):27-50
ABSTRACTGenotoxic compounds may be detoxified to non-genotoxic metabolites while many pro-carcinogens require metabolic activation to exert their genotoxicity in vivo. Standard genotoxicity assays were developed and utilized for risk assessment for over 40 years. Most of these assays are conducted in metabolically incompetent rodent or human cell lines. Deficient in normal metabolism and relying on exogenous metabolic activation systems, the current in vitro genotoxicity assays often have yielded high false positive rates, which trigger unnecessary and costly in vivo studies. Metabolically active cells such as hepatocytes have been recognized as a promising cell model in predicting genotoxicity of carcinogens in vivo. In recent years, significant advances in tissue culture and biological technologies provided new opportunities for using hepatocytes in genetic toxicology. This review encompasses published studies (both in vitro and in vivo) using hepatocytes for genotoxicity assessment. Findings from both standard and newly developed genotoxicity assays are summarized. Various liver cell models used for genotoxicity assessment are described, including the potential application of advanced liver cell models such as 3D spheroids, organoids, and engineered hepatocytes. An integrated strategy, that includes the use of human-based cells with enhanced biological relevance and throughput, and applying the quantitative analysis of data, may provide an approach for future genotoxicity risk assessment. 相似文献
39.
40.
《Vaccine》2015,33(43):5861-5867
River blindness, caused by the filarial parasite Onchocerca volvulus, is a major socio-economic and public health problem in Sub-Saharan Africa. In January 2015, The Onchocerciasis Vaccine for Africa (TOVA) Initiative has been launched with the aim of providing new tools to complement mass drug administration (MDA) of ivermectin, thereby promoting elimination of onchocerciasis in Africa. In this context we here present Onchocerca volvulus glyceraldehyde-3-phosphate dehydrogenase (Ov-GAPDH) as a possible DNA vaccine candidate. We report that in a laboratory model for filariasis, immunization with Ov-GAPDH led to a significant reduction of adult worm load and microfilaraemia in BALB/c mice after challenge infection with the filarial parasite Litomosoides sigmodontis. Mice were either vaccinated with Ov-GAPDH.DNA plasmid (Ov-pGAPDH.DNA) alone or in combination with recombinantly expressed Ov-GAPDH protein (Ov-rGAPDH). During the following challenge infection of immunized and control mice with L. sigmodontis, those formulations which included the DNA plasmid, led to a significant reduction of adult worm loads (up to 57% median reduction) and microfilaraemia (up to 94% reduction) in immunized animals. In a further experiment, immunization with a mixture of four overlapping, synthetic Ov-GAPDH peptides (Ov-GAPDHpept), with alum as adjuvant, did not significantly reduce worm loads. Our results indicate that DNA vaccination with Ov-GAPDH has protective potential against filarial challenge infection in the mouse model. This suggests a transfer of the approach into the cattle Onchocerca ochengi model, where it is possible to investigate the effects of this vaccination in the context of a natural host–parasite relationship. 相似文献